Gilead Sciences
GILD
$83.35
Share price
-0.45%
Change (1 day)
21.36%
Change (1 year)
Categories
P/S ratio for Gilead Sciences (GILD)
P/S ratio as of January 2023 (TTM): 3.85
According to Gilead Sciences's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.85248. At the end of 2022 the company had a P/S ratio of 2.85.
P/S ratio history for Gilead Sciences from 2001 to 2022
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2022 | 2.85 | -14.55% |
| 2021 | 3.33 | 12.73% |
| 2020 | 2.96 | -19.28% |
| 2019 | 3.66 | 1.12% |
| 2018 | 3.62 | 1.1% |
| 2017 | 3.58 | 15.47% |
| 2016 | 3.10 | -29.58% |
| 2015 | 4.41 | -22.34% |
| 2014 | 5.68 | -44.82% |
| 2013 | 10.3 | 78.9% |
| 2012 | 5.75 | 56.83% |
| 2011 | 3.67 | 0.28% |
| 2010 | 3.66 | -34.16% |
| 2009 | 5.55 | -36.37% |
| 2008 | 8.73 | -13.63% |
| 2007 | 10.1 | 2.11% |
| 2006 | 9.89 | -16.96% |
| 2005 | 11.9 | 0.5% |
| 2004 | 11.9 | -17.21% |
| 2003 | 14.3 | -0.5% |
| 2002 | 14.4 | -46.96% |
| 2001 | 27.1 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 4.41 | 14.47% | 🇺🇸 USA |
 Pfizer PFE | 2.45 | -36.34% | 🇺🇸 USA |
 AbbVie ABBV | 4.45 | 15.64% | 🇺🇸 USA |
 Eli Lilly LLY | 11.1 | 187.22% | 🇺🇸 USA |
 Amgen AMGN | 5.10 | 32.34% | 🇺🇸 USA |
 Biogen BIIB | 3.97 | 3.14% | 🇺🇸 USA |
 Illumina ILMN | 7.03 | 82.56% | 🇺🇸 USA |
 Vertex Pharmaceuticals VRTX | 9.44 | 145.05% | 🇺🇸 USA |
 Merck MRK | 4.56 | 18.39% | 🇺🇸 USA |